A novel CAR-T cell therapy thas proven highly effective for patients with RRMM
Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy in which T cells are genetically engineered to express T cell receptors that target a specific protein. Since its FDA approval in 2017, CAR-T cell therapy was a staple treatment for blood cancers such as multiple myeloma. New cancer cell targets are being discovered continuously, allowing for further tailoring of CAR-T cells for a specific patient.
In the multicenter CARTBCMA-HCB-01 study (NCT04309981), the efficacy and safety of a novel autologous CAR T-cell product (ARI0002h) targeting B-cell maturation antigen (BCMA) were evaluated in patients with relapsed/refractory multiple myeloma.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.